ESR1 and breast neoplasm: Importantly, XMU-MP-1 treatment had little if any effect on the proliferation of ER-negative breast tumors (n = 3; Fig. 2h), suggesting that XMU-MP-1 selectively inhibits the proliferation of patient-derived ER+ breast tumors.